Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as ...

Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer ...

Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...

By the time a Florida mom of two finally heard the words "multiple myeloma," she had already spent months being told her ...

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

In A Nutshell Men have double the odds of presenting with stage III multiple myeloma compared to women, even after accounting ...

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as ...

Men are twice as likely as women to have stage III multiple myeloma at diagnosis and appear to have a greater tumor burden than women, according to ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...

A new "double-pronged" CAR T immunotherapy recognizes two distinct features of multiple myeloma to destroy the cancer more ...